Masimo MightySat Rx is the First Fingertip Pulse Oximeter to Measure
Respiration Rate
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Feb. 15, 2017--
Masimo (NASDAQ:
MASI) announced today the CE marking of the measurement of respiration
rate from the pleth (RRpTM) on the MightySat™ Rx fingertip
pulse oximeter. MightySat Rx is a noninvasive device that measures and
displays functional oxygen saturation (SpO2), Pulse Rate (PR)
and Perfusion Index (PI) with the option to add Pleth Variability Index
(PVi®) and now, RRp.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170215005554/en/
Masimo MightySat Rx with RRp (Photo: Business Wire)
Respiration rate, or the number of breaths taken per minute, typically
requires manually counting breaths with a timer and then converting to a
per minute rate, or being fitted with chest leads or straps that can be
inconvenient. With the addition of RRp to MightySat Rx, respiration rate
can conveniently be measured using the same fingertip sensor that
measures SpO2, PR, PI, and PVi (a measurement of the dynamic
changes in PI that occur during the respiratory cycle). RRp is measured
only when the respiratory movement-induced signal is present in the
pulsatile waveform and may not be available during certain conditions,
such as very irregular breathing and excessive movement.
MightySat Rx is indicated for use with both adult and pediatric patients
during both no motion and motion conditions, who are well or poorly
perfused, in hospitals, hospital-type facilities, mobile, and home
environments. It offers a Bluetooth wireless interface to the Masimo
Professional Health mobile application to track, trend, and communicate
measurements. MightySat Rx features the same Measure-through Motion and
Low Perfusion™ SET® pulse oximetry available in a variety of
bedside Masimo and OEM monitors. Masimo SET® addresses the
challenges of low perfusion and motion artifact that limit conventional
pulse oximetry by harnessing the power of adaptive filters to reduce
measurement inaccuracy. Infection control issues aside, Masimo SET®
performance benefits are maximized by choosing the correct sensor type
for the applicable use scenario: adhesive sensors for continuous
monitoring, reusable cabled sensors for short-term monitoring and
MightySat Rx fingertip oximeters for spot-checks on those who are not
moving excessively and do not have very poor perfusion. Masimo SET®
helps clinicians monitor oxygen saturation and pulse rate during motion
and low perfusion for more than 100 million patients a year1
and is the primary pulse oximetry at top hospitals, including 9 of the
top 10 hospitals listed in the 2016-17 U.S. News and World Report Best
Hospitals Honor Roll.2
“MightySat Rx is our smallest, most compact pulse oximeter, and as such
is particularly versatile, offering the convenience of portability,”
stated Joe Kiani, Chairman and CEO of Masimo. “We are happy to be able
to increase its capability with the addition of RRp, and to continue
innovating in the field of mobile monitoring devices for the
professional caregiver market.”
RRp does not have 510(k) clearance and is not available in the U.S.
@MasimoInnovates |
#Masimo
References
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to helps clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring in post-surgical wards, reduce
rapid response activations and costs.3,4,5 Masimo SET®
is estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood constituents
that previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVi®) and Oxygen Reserve
Index (ORi™), in addition to SpO2, pulse rate, and perfusion
index (PI). Studies with SpHb have shown reductions in unnecessary blood
transfusion*,6,7 and when used with PVi, reductions in length
of hospital stay8 and 30- and 90-day mortality.9
In 2014, Masimo introduced Root®, an intuitive patient
monitoring and connectivity platform with the Masimo Open Connect™
(MOC-9™) interface, enabling other companies to augment Root with new
features and measurement capabilities. Masimo is also taking an active
leadership role in mHealth with products such as the Radius-7™ wearable
patient monitor, iSpO2® pulse oximeter for
smartphones, and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
*Clinical decisions regarding red blood cell transfusions should be
based on the clinician’s judgment considering, among other factors:
patient condition, continuous SpHb monitoring, and laboratory diagnostic
tests using blood samples.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring
during Orthopedia Surgery: A Randomized Trial. J Blood Disorders
Transf. 2014. 5:9. 2.
-
Awada WN et al. Continuous and noninvasive hemoglobin monitoring
reduces red blood cell transfusion during neurosurgery: a prospective
cohort study. J Clin Monit Comput. 2015 Feb 4.
-
Thiele RH et al. Standardization of Care: Impact of an Enhanced
Recovery Protocol on Length of Stay, Complications, and Direct Costs
after Colorectal Surgery. JACS (2015). doi:
10.1016/j.jamcollsurg.2014.12.042.
-
Nathan N et al. Impact of Continuous Perioperative SpHb Monitoring.
Proceedings from the 2016 ASA Annual Meeting, Chicago. Abstract #A1103.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of MightySat™ Rx and SET® pulse oximetry. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo MightySat Rx and SET®
pulse oximetry, contribute to positive clinical outcomes and patient
safety; as well as other factors discussed in the "Risk Factors" section
of our most recent reports filed with the Securities and Exchange
Commission ("SEC"), which may be obtained for free at the SEC's website
at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005554/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
[email protected]